Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

OBJECTIVE: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Huh, Warner K., Rosenberg, Julie Ann, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361700/
https://www.ncbi.nlm.nih.gov/pubmed/28344818
http://dx.doi.org/10.1186/s40661-017-0045-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361700/
https://www.ncbi.nlm.nih.gov/pubmed/28344818
http://dx.doi.org/10.1186/s40661-017-0045-x

Ejemplares similares